NCT01810939 - A Two-Part, Single-Blind, Phase 3 Study Evaluating the Efficacy and Safety of Patiromer for the Treatment of Hyperkalemia (OPAL) | Biotech Hunter

Enrollment

243

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

July 31, 2013

Study Completion Date

August 31, 2013

Conditions

Chronic Kidney Disease (CKD)Hyperkalemia (HK)

Interventions

DRUG

Patiromer

DRUG

Placebo

Trial Locations (58)

3000

Investigator Site 1802, Celje

3680

Investigator Site 1911, Kyiv

4000

Investigator Site 2101, Roskilde

4270

Investigator Site 1803, Jesenice

7000

Investigator Site 2107, Fredericia

8200

Investigator Site 2103, Aarhus N

8800

Investigator Site 2105, Viborg

10000

Investigator Site 1104, Zagreb

Investigator Site 1105, Zagreb

Investigator Site 1106, Zagreb

11000

Investigator Site 1703, Belgrade

11355

Investigator Site 3134, Flushing

18017

Investigator Site 3107, Bethlehem

23000

Investigator Site 1707, Zrenjanin

26300

Investigator Site 1710, Vršac

27100

Investigator Site 2201, Pavia

30909

Investigator Site 3120, Augusta

31000

Investigator Site 1102, Osijek

32132

Investigator Site 3105, Edgewater

33021

Investigator Site 3113, Hollywood

33952

Investigator Site 3106, Port Charlotte

47000

Investigator Site 1103, Karlovac

61007

Investigator Site 1904, Kharkiv

61018

Investigator Site 1903, Kharkiv

61039

Investigator Site 1908, Kharkiv

63640

Investigator Site 3102, Farmington

64111

Investigator Site 3104, Kansas City

69001

Investigator Site 1907, Zaporizhzhia

69118

Investigator Site 1906, Zaporizhzhia

76018

Investigator Site 1915, Ivano-Frankivsk

78229

Investigator Site 3110, San Antonio

90025

Investigator Site 3133, Los Angeles

91045

Investigator Site 1914, Luhansk

91702

Investigator Site 3121, Azusa

93003

Investigator Site 3130, Ventura

93110

Investigator Site 3129, Santa Barbara

95825

Investigator Site 3103, Sacramento

66 902

Investigator Site 1205, Znojmo

0102

Investigator Site 1308, Tbilisi

0144

Investigator Site 1312, Tbilisi

0159

Investigator Site 1301, Tbilisi

Investigator Site 1302, Tbilisi

Investigator Site 1304, Tbilisi

Investigator Site 1305, Tbilisi

Investigator Site 1306, Tbilisi

Investigator Site 1307, Tbilisi

Investigator Site 1309, Tbilisi

Investigator Site 1310, Tbilisi

Investigator Site 1311, Tbilisi

0186

Investigator Site 1303, Tbilisi

H-8230

Investigator Site 1410, Balatonfüred

H-1133

Investigator Site 1415, Budapest

H-9024

Investigator Site 1401, Győr

H-3000

Investigator Site 1406, Hatvan

H-5100

Investigator Site 1405, Jászberény

H-2143

Investigator Site 1411, Kistarcsa

H-8200

Investigator Site 1407, Veszprém

04114

Investigator Site 1909, Kyiv

All Listed Sponsors

lead

Relypsa, Inc.

INDUSTRY